Capital One initiated coverage of Carisma Therapeutics with an Overweight rating and $10 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARM:
- Carisma Therapeutics to report latest data from Phase 1 trial of CT-0508
- Carisma Therapeutics price target raised to $11 from $10 at H.C. Wainwright
- Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Carisma Therapeutics reports Q2 EPS (49c), consensus (60c)
